Steven Paul, M.D.

Chief Executive OfficerKaruna Pharmaceuticals

Dr. Paul is the CEO at Karuna Pharmaceuticals, a biotechnology company developing medicines for schizophrenia, Alzheimer’s disease and pain. An expert in central nervous system (CNS) drug discovery and development, Dr. Paul is a co-founder of Sage Therapeutics, a co-founder of Voyager Therapeutics where he served as president, chief executive officer, and member of the Board of Directors, and is a member of the Board of Directors at Alnylam Pharmaceuticals. He spent 17 years at Eli Lilly and Company, during which time he served in several key leadership roles, including executive vice president of Science and Technology and president of the Lilly Research Laboratories, where he was responsible for the company’s overall research and development strategy, expanding its efforts in neuroscience, diabetes, oncology, inflammation and biotechnology, resulting in a pipeline of approximately 70 new molecular entities. At Lilly, Dr. Paul also helped oversee the development of xanomeline. Prior to Lilly, Dr. Paul spent 18 years at the National Institutes of Health (NIH) and served as the scientific director of the National Institute of Mental Health (NIMH).  Dr. Paul is the former director of the Appel Alzheimer Disease Research Institute at Weill Cornell Medical College and is currently an adjunct professor of Psychiatry at Washington University of St Louis School of Medicine. Dr. Paul has authored or co-authored more than 550 papers and book chapters. He is an elected fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine (NAM) of the National Academy of Sciences (NAS). He is also an elected fellow of the American College of Neuropsychopharmacology (ACNP) and served as ACNP President (1999). Dr. Paul is the chairman of the Board of the Foundation for the NIH (FNIH) and previously served on the Science Board of the U.S. Food and Drug Administration (FDA) in addition to serving on many other advisory committees and receiving many awards and honors for his work in neuropsychiatry.

Sessions
Oct 24 8:15 AM Progress in treating neurodegenerative disease

A panel discussion